United Therapeutics Corp (UTH.MU)
| Previous Close | 299.30 |
| Open | 299.20 |
| Bid | 295.20 x 0 |
| Ask | 297.70 x 0 |
| Day's Range | 299.20 - 299.20 |
| 52 Week Range | 193.70 - 301.00 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
United Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., June 27, 2024--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced the addition of former Minnesota Commissioner of Health Jan Malcolm to its Board of Directors. Ms. Malcolm was elected by the company’s shareholders at its annual meeting held on June 26, 2024.
- Business Wire
United Therapeutics Corporation to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., June 05, 2024--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company’s operations during a fireside chat session at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, Florida.
- Business Wire
United Therapeutics Corporation Reports First Quarter 2024 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., May 01, 2024--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2024. Total revenues in the first quarter of 2024 grew 34 percent year-over-year to $677.7 million, compared to $506.9 million in the first quarter of 2023.
